Impact of IL-1 signalling on experimental uveitis and arthritis

Annals of the Rheumatic Diseases

Volumn 71, Issue 5, 2012, Pages 753-760

  Planck, Stephen R ^a,b   Woods, April ^a   Clowers, Jenna S ^a,c   Nicklin, Martin J ^d   Rosenbaum, James T ^a,b   Rosenzweig, Holly L ^a,b,c  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c PORTLAND VA MEDICAL CENTER   (United States)

^d UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR ALPHA; INTERLEUKIN 1 RECEPTOR TYPE II; LIPOPOLYSACCHARIDE; REGULATOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ANKLE; ARTHRITIS; ARTICLE; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE PREDISPOSITION; FEMALE; GENE SILENCING; HISTOPATHOLOGY; INTRAVITAL VIDEOMICROSCOPY; KNEE; MICROSCOPY; MOUSE; NONHUMAN; PATHOGENESIS; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; UVEITIS;

ANIMALS; ARTHRITIS; DISEASE MODELS, ANIMAL; EYE; FEMALE; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1; JOINTS; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; MICROSCOPY, VIDEO; ORGAN SPECIFICITY; SIGNAL TRANSDUCTION; UVEITIS;

EID: 84859485644     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2011-200556     Document Type: Article

References (44)

1. Deal watch. XOMA and Servier to develop anti-IL-1β antibody for inflammatory diseases. Nat Rev Drug Discov 2011;10:166.
2. Gul A, Artim-Esen B, Solinger AM, et al. Safe, rapid-onset, and sustained biological activity of IL-1 regulating antibody XOMA 052 in resistant uveitis of Behcet's idsease: results of a pilot trial. Arth Rheum 2010;62:1308.
3. Chang JH, Wakefield D. Uveitis: a global perspective. Ocul Immunol Inflamm 2002;10:263-79. (Pubitemid 36886369)
4. Reveille JD. The genetic basis of spondyloarthritis. Ann Rheum Dis 2011;70:i44-50.
5. Ali A, Samson CM. Seronegative spondyloarthropathies and the eye. Curr Opin Ophthalmol 2007;18:476-80. (Pubitemid 351339401)
6. Goldbach-Mansky R, Kastner DL. Autoinflammation: the prominent role of IL-1 in monogenic autoinflammatory diseases and implications for common illnesses. J Allergy Clin Immunol 2009;124:1141-9; quiz 1150-1.
7. Masters SL, Simon A, Aksentijevich I, et al. Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease (*). Annu Rev Immunol 2009;27:621-68.
8. Henderson C, Goldbach-Mansky R. Monogenic autoinflammatory diseases: new insights into clinical aspects and pathogenesis. Curr Opin Rheumatol 2010;22:567-78.
9. McGarry F, Neilly J, Anderson N, et al. A polymorphism within the interleukin 1 receptor antagonist (IL-1Ra) gene is associated with ankylosing spondylitis. Rheumatology (Oxford) 2001;40:1359-64.
10. Gabay C, Lamacchia C, Palmer G. IL-1 pathways in inflammation and human diseases. Nat Rev Rheumatol 2010;6:232-41.
11. Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 2011;117:3720-32.
12. Djouadi K, Nedelec B, Tamouza R, et al. Interleukin 1 gene cluster polymorphisms in multiplex families with spondylarthropathies. Cytokine 2001;13:98-103. (Pubitemid 32579315)
13. Maksymowych WP, Reeve JP, Reveille JD, et al. High-throughput single-nucleotide polymorphism analysis of the IL1RN locus in patients with ankylosing spondylitis by matrix-assisted laser desorption ionization-time-of- flight mass spectrometry. Arthritis Rheum 2003;48:2011-18. (Pubitemid 36828696)
14. Hutyrová B, Pantelidis P, Drábek J, et al. Interleukin-1 gene cluster polymorphisms in sarcoidosis and idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2002;165:148-51. (Pubitemid 34084448)
15. Coskun M, Bacanli A, Sallakci N, et al. Specific interleukin-1 gene polymorphisms in Turkish patients with Behçet's disease. Exp Dermatol 2005;14:124-9. (Pubitemid 40277579)
16. Karasneh J, Hajeer AH, Barrett J, et al. Association of specific interleukin 1 gene cluster polymorphisms with increased susceptibility for Behcet's disease. Rheumatology (Oxford) 2003;42:860-4. (Pubitemid 37220935)
17. Ferraccioli G, Bracci-Laudiero L, Alivernini S, et al. Interleukin-1β and interleukin-6 in arthritis animal models: roles in the early phase of transition from acute to chronic inflammation and relevance for human rheumatoid arthritis. Mol Med 2010;16:552-7.
18. Nicklin MJ, Hughes DE, Barton JL, et al. Arterial inflammation in mice lacking the interleukin 1 receptor antagonist gene. J Exp Med 2000;191:303-12.
19. Horai R, Saijo S, Tanioka H, et al. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J Exp Med 2000;191:313-20. (Pubitemid 30060920)
20. Shepherd J, Little MC, Nicklin MJ. Psoriasis-like cutaneous inflammation in mice lacking interleukin-1 receptor antagonist. J Invest Dermatol 2004;122:665-9. (Pubitemid 38471334)
21. Nakajima A, Matsuki T, Komine M, et al. TNF, but not IL-6 and IL-17, is crucial for the development of T cell-independent psoriasis-like dermatitis in Il1rn-/- mice. J Immunol 2010;185:1887-93.
22. Shepherd J, Nicklin MJ. Elastic-vessel arteritis in interleukin-1 receptor antagonist-deficient mice involves effector Th1 cells and requires interleukin-1 receptor. Circulation 2005;111:3135-40. (Pubitemid 40847792)
23. Becker MD, Nobiling R, Planck SR, et al. Digital video-imaging of leukocyte migration in the iris: intravital microscopy in a physiological model during the onset of endotoxin-induced uveitis. J Immunol Methods 2000;240:23-37. (Pubitemid 30347399)
24. Rosenzweig HL, Martin TM, Jann MM, et al. NOD2, the gene responsible for familial granulomatous uveitis, in a mouse model of uveitis. Invest Ophthalmol Vis Sci 2008;49:1518-24.
25. Kezic J, Taylor S, Gupta S, et al. Endotoxin-induced uveitis is primarily dependent on radiation-resistant cells and on MyD88 but not TRIF. J Leukoc Biol 2011;90:305-11.
26. Rosenzweig HL, Jann MJ, Vance EE, et al. Nucleotide-binding oligomerization domain 2 and Toll-like receptor 2 function independently in a murine model of arthritis triggered by intraarticular peptidoglycan. Arthritis Rheum 2010;62:1051-9.
27. Rosenzweig HL, Martin TM, Planck SR, et al. Activation of NOD2 in vivo induces IL-1beta production in the eye via caspase-1 but results in ocular inflammation independently of IL-1 signaling. J Leukoc Biol 2008;84:529-36.
28. Abdollahi-Roodsaz S, Joosten LA, Koenders MI, et al. Stimulation of TLR2 and TLR4 differentially skews the balance of T cells in a mouse model of arthritis. J Clin Invest 2008;118:205-16.
29. Rosenzweig HL, Clowers JS, Nunez G, et al. Dectin-1 and NOD2 mediate cathepsin activation in zymosan-induced arthritis in mice. Inflamm Res 2011;60:705-14.
30. Abdollahi-Roodsaz S, Joosten LA, Roelofs MF, et al. Inhibition of Toll-like receptor 4 breaks the inflammatory loop in autoimmune destructive arthritis. Arthritis Rheum 2007;56:2957-67. (Pubitemid 47502742)
31. Abdollahi-Roodsaz S, Joosten LA, Koenders MI, et al. Local interleukin-1- driven joint pathology is dependent on toll-like receptor 4 activation. Am J Pathol 2009;175:2004-13.
32. Rosenbaum JT, McDevitt HO, Guss RB, et al. Endotoxin-induced uveitis in rats as a model for human disease. Nature 1980;286:611-13. (Pubitemid 10015368)
33. Aksentijevich I, Masters SL, Ferguson PJ, et al. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med 2009;360:2426-37.
34. Reddy S, Jia S, Geoffrey R, et al. An autoinflammatory disease due to homozygous deletion of the IL1RN locus. N Engl J Med 2009;360:2438-44.
35. Smith JR, Levinson RD, Holland GN, et al. Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum 2001;45:252-7. (Pubitemid 32952905)
36. Lim LL, Fraunfelder FW, Rosenbaum JT. Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum 2007;56:3248-52. (Pubitemid 47585419)
37. Verma MJ, Lloyd A, Rager H, et al. Chemokines in acute anterior uveitis. Curr Eye Res 1997;16:1202-8. (Pubitemid 27515674)
38. Matzinger P, Kamala T. Tissue-based class control: the other side of tolerance. Nat Rev Immunol 2011;11:221-30.
39. Rosenbaum JT, Boney RS. Activity of an interleukin 1 receptor antagonist in rabbit models of uveitis. Arch Ophthalmol 1992;110:547-9.
40. Trittibach P, Barker SE, Broderick CA, et al. Lentiviral-vector-mediated expression of murine IL-1 receptor antagonist or IL-10 reduces the severity of endotoxin-induced uveitis. Gene Ther 2008;15:1478-88.
41. Smith JR, Hart PH, Coster DJ, et al. Mice deficient in tumor necrosis factor receptors p55 and p75, interleukin-4, or inducible nitric oxide synthase are susceptible to endotoxin-induced uveitis. Invest Ophthalmol Vis Sci 1998;39:658-61. (Pubitemid 28110703)
42. Brito BE, O'Rourke LM, Pan Y, et al. Murine endotoxin-induced uveitis, but not immune complex-induced uveitis, is dependent on the IL-8 receptor homolog. Curr Eye Res 1999;19:76-85. (Pubitemid 29308832)
43. Nold MF, Nold-Petry CA, Zepp JA, et al. IL-37 is a fundamental inhibitor of innate immunity. Nat Immunol 2010;11:1014-22.
44. Arend WP. The balance between IL-1 and IL-1Ra in disease. Cytokine Growth Factor Rev 2002;13:323-40.